Latest News

Starpharma receives $7.7M R&D tax incentive refund (ASX Announcement)

Jan 20th, 2022

Starpharma today announced it has received a $7.7M research and development (R&D) tax incentive refund related to the company’s Australian and international R&D expenses from the 2021 financial year. The tax refund is for eligible R&D activities across Starpharma’s portfolio, including the company’s DEP® oncology products and VIRALEZE™ antiviral nasal spray.

Read More

Shareholder Newsletter December 2021

Dec 16th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.

Read More

VIRALEZE™ antiviral nasal spray registered in Saudi Arabia (ASX Announcement)

Dec 14th, 2021

Starpharma today announced that VIRALEZE™ antiviral nasal spray has been registered for sale in Saudi Arabia. This is the first registration for VIRALEZE™ in the Middle East and registration in Saudi Arabia is an important step for other countries in the region.

Read More

VIRALEZE™ successfully launched in Vietnam (ASX Announcement)

Dec 13th, 2021

Starpharma today announced that since signing the commercial arrangement for VIRALEZE™ antiviral nasal spray in Vietnam, the company has received orders in excess of A$2 million, since late October. Some orders have already been delivered with further product expected to be delivered in the New Year. VIRALEZE™ successfully launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.

Read More

In the media

Starpharma announces early orders following Vietnam distribution agreement

Dec 14th, 2021

BiotechDispatch report on Starpharma's latest announcement related to the launch of VIRALEZE™ in Vietnam. 

Read More

Starpharma (ASX:SPL) tables $2m in Vietnam VIRALEZE orders

Dec 13th, 2021

"Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totaling more than $2 million for Vietnam", as reported in The Market Herald.

Read More

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Read More

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha. 

Read More

Shareholder Updates

Shareholder Newsletter December 2021

Dec 16th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – December 2021 is now available to view online.

Read More

Shareholder Update April 2021

Apr 28th, 2021

The Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) Shareholder Update – April 2021 is now available to view online.

Read More

Sign up to receive news here